Home » Authors » Kim Coghill

Kim Coghill

Articles

ARTICLES

OSI Acquiring Cell Pathways In Stock Deal Valued At $32M

Feb. 11, 2003

OSI Acquiring Cell Pathways In Stock Deal Valued At $32M

Feb. 11, 2003

ImClone's Erbitux Being Offered Through Limited Access Program

Feb. 10, 2003

ImClone's Erbitux Being Offered Through Limited Access Program

Feb. 10, 2003

Ingelheim Starts Phase III Trials Of Non-Peptidic Protease Inhibitor

Feb. 7, 2003

BioMimetic Licenses PDGF From ZymoGenetics For Bone Diseases

Feb. 7, 2003

Corixa, Japan Tobacco Rework Lung Cancer Vaccine Agreement

Feb. 6, 2003

Bipartisan Group Supports Research, Therapeutic Cloning

Feb. 6, 2003

Corixa, Japan Tobacco Rework Lung Cancer Vaccine Agreement

Feb. 6, 2003

Bipartisan Group Supports Research, Therapeutic Cloning

Feb. 6, 2003

View All Articles by Kim Coghill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...